• Lipid Scrambling and Ferroptosis: TMEM16F as a Therapeutic T

  2026-05-29

  The reference study uncovers TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis by orchestrating plasma membrane remodeling and mitigating oxidative membrane damage. These findings highlight new mechanistic links between iron-driven lipid peroxidation, immune activation, and potential therapeutic strategies for cancer.

• ω-Agatoxin IVA Blocks Cav2.1 Channels to Suppress Seizures i

  2026-05-29

  This study demonstrates that ω-Agatoxin IVA, a selective P/Q-type (Cav2.1) calcium channel blocker, significantly delays seizure onset and suppresses epileptogenesis in a rat model while promoting neuroprotection via BDNF upregulation and reduced apoptosis. The findings suggest a promising mechanistic pathway for antiepileptic therapy distinct from current clinical agents.

• Roscovitine: Strategic Leverage in Translational Oncology

  2026-05-28

  Explore how Roscovitine (Seliciclib, CYC202) empowers translational researchers to interrogate cell cycle arrest, overcome therapy resistance, and design next-generation protocols in cancer biology. Anchored in mechanistic insight and emerging evidence, this article bridges selective CDK inhibition with actionable strategies for preclinical and translational pipelines.

• Cell Lineage and Thioguanine Sensitivity in Relapsed Childho

  2026-05-28

  This study elucidates how immunophenotypic cell lineage affects in vitro drug resistance in relapsed childhood acute lymphoblastic leukemia (ALL). Notably, relapsed T-cell ALL exhibits increased sensitivity to thiopurine agents like thioguanine, supporting more tailored therapeutic strategies.

• Erastin as a Ferroptosis Inducer: Protocols and Cancer Resea

  2026-05-27

  Erastin is a benchmark ferroptosis inducer with unique selectivity for RAS/BRAF-mutant tumor cells, providing a powerful tool for dissecting oxidative cell death pathways. This article translates recent research breakthroughs into actionable workflows, protocol enhancements, and troubleshooting guidance to empower advanced cancer biology research.

• Deferoxamine Mesylate (SKU B6068): Data-Driven Lab Solutions

  2026-05-27

  This article presents scenario-driven guidance for leveraging Deferoxamine mesylate (SKU B6068) in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and validated workflows, we detail how this iron-chelating agent supports reproducible, sensitive, and robust outcomes in biomedical research.

• JNJ-26854165 (Serdemetan): Precision HDM2 Inhibition in Adva

  2026-05-26

  Explore the unique advantages of JNJ-26854165 (Serdemetan) as a precision HDM2 ubiquitin ligase antagonist in cancer research. This article delivers an in-depth analysis of its mechanism, advanced protocols, and the pivotal in vitro insights that elevate assay design beyond conventional approaches.

• Machine Learning Accelerates Senolytic Discovery in Cell Mod

  2026-05-26

  The referenced study demonstrates a machine learning approach to senolytic discovery, identifying new compounds effective at selectively eliminating senescent cells. This innovation reduces screening costs and expands the toolkit for targeting cellular senescence in disease models.

• Meropenem: Ultra-Broad-Spectrum β-Lactam Carbapenem Profile

  2026-05-25

  Meropenem is a β-lactam antibiotic carbapenem with ultra-broad-spectrum activity, effective against both Gram-negative and Gram-positive bacteria. Its mechanism involves inhibition of penicillin-binding proteins, offering robust activity even against resistant strains. Recent evidence details its utility in research modeling multidrug resistance and septicemia.

• Molidustat (BAY85-3934): Applied Workflows in Renal Anemia M

  2026-05-25

  Molidustat (BAY85-3934) empowers researchers to precisely stimulate erythropoietin and model oxygen-sensing pathway dynamics in chronic kidney disease anemia. This guide translates mechanistic insights and recent findings into actionable protocols and troubleshooting strategies that maximize translational impact.

• Structure-Based Inhibitor Screening of SARS-CoV-2 NSP15

  2026-05-24

  This study presents a structure-based virtual screening of natural products targeting NSP15, a key SARS-CoV-2 endoribonuclease involved in immune evasion. The identification of thymopentin and oleuropein as potent, stable NSP15 inhibitors highlights new avenues for antiviral drug development and mechanistic study.

• Cyclic Pifithrin-α Hydrobromide: Reliable p53 Inhibition for

  2026-05-23

  Discover how Cyclic Pifithrin-α hydrobromide (SKU A4477) addresses key challenges in apoptosis inhibition, DNA damage response modulation, and protection from gamma irradiation. This article delivers scenario-driven guidance for biomedical researchers, focusing on experimental reliability, validated protocol parameters, and vendor selection rooted in scientific evidence.

• Demethyleneberberine Inhibits IL-1β Maturation via TLR4-Mito

  2026-05-22

  This study elucidates how demethyleneberberine (DMB), a natural isoquinoline alkaloid, suppresses inflammatory IL-1β maturation by inhibiting TLR4-mitochondria signaling. The findings clarify DMB’s mechanism in ulcerative colitis models and provide a foundation for its use as an anti-inflammatory compound in translational research.

• Macrophage EV-miR-660 Drives NF-κB–Mediated Breast Cancer Pr

  2026-05-22

  This study uncovers how tumor-associated macrophages (TAMs) promote breast cancer metastasis via extracellular vesicles (EVs) carrying microRNA-660. The miR-660 cargo suppresses KLHL21, leading to NF-κB pathway activation in cancer cells, highlighting a novel axis for therapeutic intervention.

• Ridaforolimus (Deforolimus): Potent mTOR Inhibitor for Cance

  2026-05-21

  Ridaforolimus (Deforolimus, MK-8669) is a nanomolar-potency, selective mTOR pathway inhibitor with proven antiproliferative and anti-angiogenic activity in diverse cancer cell models. Its mechanism centers on robust mTOR signaling blockade, validated in both in vitro and in vivo systems. This article provides an evidence-dense dossier for laboratory integration, protocol optimization, and boundary-aware use.

16518 records 1/1102 page Next 12345 下5页 Last page